159 related articles for article (PubMed ID: 38392076)
21. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy.
Henson BS; Inglehart MR; Eisbruch A; Ship JA
Oral Oncol; 2001 Jan; 37(1):84-93. PubMed ID: 11120488
[TBL] [Abstract][Full Text] [Related]
22. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer.
Gornitsky M; Shenouda G; Sultanem K; Katz H; Hier M; Black M; Velly AM
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Jul; 98(1):45-52. PubMed ID: 15243470
[TBL] [Abstract][Full Text] [Related]
23. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
24. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia.
Blitzer GC; Glazer T; Burr A; Gustafson S; Ganz O; Meyers R; McDowell KA; Nickel KP; Mattison RJ; Weiss M; Chappell R; Rogus-Pulia NM; Galipeau J; Kimple RJ
Cytotherapy; 2023 Nov; 25(11):1139-1144. PubMed ID: 37589639
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of effect of transcutaneous electrical nerve stimulation on salivary flow rate in radiation induced xerostomia patients: a pilot study.
Lakshman AR; Babu GS; Rao S
J Cancer Res Ther; 2015; 11(1):229-33. PubMed ID: 25879367
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.
LeVeque FG; Montgomery M; Potter D; Zimmer MB; Rieke JW; Steiger BW; Gallagher SC; Muscoplat CC
J Clin Oncol; 1993 Jun; 11(6):1124-31. PubMed ID: 8501499
[TBL] [Abstract][Full Text] [Related]
27. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
[TBL] [Abstract][Full Text] [Related]
28. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients.
Kakoei S; Haghdoost AA; Rad M; Mohammadalizadeh S; Pourdamghan N; Nakhaei M; Bahador M
Arch Iran Med; 2012 Apr; 15(4):214-8. PubMed ID: 22424038
[TBL] [Abstract][Full Text] [Related]
29. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
[TBL] [Abstract][Full Text] [Related]
30. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients.
Malouf JG; Aragon C; Henson BS; Eisbruch A; Ship JA
Cancer Detect Prev; 2003; 27(4):305-10. PubMed ID: 12893079
[TBL] [Abstract][Full Text] [Related]
31. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction.
Blitzer GC; Rogus-Pulia NM; Mattison RJ; Varghese T; Ganz O; Chappell R; Galipeau J; McDowell KA; Meyers RO; Glazer TA; Kimple RJ
Cytotherapy; 2022 May; 24(5):534-543. PubMed ID: 35183442
[TBL] [Abstract][Full Text] [Related]
32. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
[TBL] [Abstract][Full Text] [Related]
33. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Cohort Study Analyzing Radiation-Induced Xerostomia and Quality of Life of Head and Neck Cancer Patients Treated With Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy Techniques at a Tertiary Cancer Center in Eastern India.
Sahoo B; Padhi S; Patra AC; Mahapatra BR; Mishra T; Mishra SR; Patro KC
Cureus; 2023 Mar; 15(3):e36442. PubMed ID: 37090370
[TBL] [Abstract][Full Text] [Related]
35. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II).
Lynggaard CD; Grønhøj C; Christensen R; Fischer-Nielsen A; Melchiors J; Specht L; Andersen E; Mortensen J; Oturai P; Barfod GH; Haastrup EK; Møller-Hansen M; Haack-Sørensen M; Ekblond A; Kastrup J; Jensen SB; von Buchwald C
Stem Cells Transl Med; 2022 May; 11(5):478-489. PubMed ID: 35435231
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase III trial for alleviating radiation-induced xerostomia with chewing gum.
Kaae JK; Stenfeldt L; Hyrup B; Brink C; Eriksen JG
Radiother Oncol; 2020 Jan; 142():72-78. PubMed ID: 31606226
[TBL] [Abstract][Full Text] [Related]
37. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of implementing the OHIP-14 questionnaire to assess the impact of xerostomia and hyposalivation on quality of life in patients with primary Sjögren's syndrome.
Serrano J; López-Pintor RM; Fernández-Castro M; Ramírez L; Sanz M; López J; Blázquez MÁ; González JJ; Hernández G;
J Oral Pathol Med; 2022 Oct; 51(9):810-817. PubMed ID: 35998227
[TBL] [Abstract][Full Text] [Related]
39. Role of minor salivary glands in developing patient-rated xerostomia and sticky saliva during day and night.
Beetz I; Schilstra C; Visink A; van der Schaaf A; Bijl HP; van der Laan BF; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2013 Nov; 109(2):311-6. PubMed ID: 23953752
[TBL] [Abstract][Full Text] [Related]
40. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.
Scrimger RA; Seikaly H; Vos LJ; Harris J; O'Connell D; Ghosh S; Debenham B; Jha N
Head Neck; 2018 Nov; 40(11):2353-2361. PubMed ID: 30175876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
